A Prospective, Open-Label, Single-Arm, Phase 2, Multicenter Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Subjects With T-Cell Prolymphocytic Leukemia
Latest Information Update: 14 Sep 2023
At a glance
- Drugs Ibrutinib (Primary) ; Venetoclax (Primary)
- Indications T-cell prolymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors AbbVie; AbbVie Germany
Most Recent Events
- 19 Nov 2021 Status changed from active, no longer recruiting to completed.
- 15 Jul 2021 This trial has been completed in Finland, according to European Clinical Trials Database record.
- 06 Apr 2021 Planned End Date changed from 21 Sep 2024 to 13 Sep 2022.